Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation.
作者信息
Salazar Jonathan A, Goldsmith Jeffrey D, Bousvaros Athos, Tracy Michaela
机构信息
Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Division of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
出版信息
Gastroenterol Hepatol (N Y). 2024 Oct;20(9):546-549.
Abstract
摘要
相似文献
1
Cytomegalovirus Colitis in a Patient With Ulcerative Colitis With Loss of Corticosteroid Response Upon Upadacitinib Initiation.
Gastroenterol Hepatol (N Y). 2024 Oct;20(9):546-549.
2
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.
Crohns Colitis 360. 2024 Feb 28;6(1):otae014. doi: 10.1093/crocol/otae014. eCollection 2024 Jan.
3
Impact of Baseline Corticosteroid Use on the Efficacy and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Post Hoc Analysis of the Phase 3 Clinical Trial Programme.
J Crohns Colitis. 2024 May 31;18(5):695-707. doi: 10.1093/ecco-jcc/jjad190.
4
Effectiveness and safety of upadacitinib in acute severe ulcerative colitis patients from single Chinese IBD Center: a monocentric study.
Clin Exp Med. 2024 Sep 30;24(1):233. doi: 10.1007/s10238-024-01468-z.
5
The role of upadacitinib in the treatment of ulcerative colitis.
Immunotherapy. 2023 Jul;15(10):713-727. doi: 10.2217/imt-2022-0299. Epub 2023 Apr 27.
6
Systematic Review with Meta-analysis: Efficacy and Safety of Upadacitinib in Managing Moderate-to-Severe Crohn's Disease and Ulcerative Colitis.
Clin Drug Investig. 2024 Jun;44(6):371-385. doi: 10.1007/s40261-024-01364-0. Epub 2024 May 23.
7
Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials.
Lancet. 2022 Jun 4;399(10341):2113-2128. doi: 10.1016/S0140-6736(22)00581-5. Epub 2022 May 26.
8
Upadacitinib Salvage Therapy for Infliximab-Experienced Patients with Acute Severe Ulcerative Colitis.
J Crohns Colitis. 2023 Dec 30;17(12):2033-2036. doi: 10.1093/ecco-jcc/jjad115.
9
Efficacy and safety of upadacitinib maintenance therapy for moderately to severely active ulcerative colitis in patients responding to 8 week induction therapy (U-ACHIEVE Maintenance): overall results from the randomised, placebo-controlled, double-blind, phase 3 maintenance study.
Lancet Gastroenterol Hepatol. 2023 Nov;8(11):976-989. doi: 10.1016/S2468-1253(23)00208-X. Epub 2023 Sep 9.
10
Pharmacokinetics of Upadacitinib in Healthy Subjects and Subjects With Rheumatoid Arthritis, Crohn's Disease, Ulcerative Colitis, or Atopic Dermatitis: Population Analyses of Phase 1 and 2 Clinical Trials.
J Clin Pharmacol. 2020 Apr;60(4):528-539. doi: 10.1002/jcph.1550. Epub 2019 Nov 7.
本文引用的文献
1
Cytomegalovirus Colitis in a Patient with Severe Treatment Refractory Ulcerative Colitis.
Crohns Colitis 360. 2024 Feb 28;6(1):otae014. doi: 10.1093/crocol/otae014. eCollection 2024 Jan.
2
Cytomegalovirus Retinitis in a Patient Taking Upadacitinib: A Case Report.
Cureus. 2023 Nov 5;15(11):e48337. doi: 10.7759/cureus.48337. eCollection 2023 Nov.
3
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes.
Clin Exp Gastroenterol. 2023 Mar 7;16:21-28. doi: 10.2147/CEG.S367086. eCollection 2023.
4
JAK kinase inhibitors and varicella zoster virus infection in patients with rheumatoid arthritis. Systematic review of the literature.
Reumatol Clin (Engl Ed). 2022 Oct;18(8):453-458. doi: 10.1016/j.reumae.2021.06.001. Epub 2021 Dec 8.
5
JAK inhibitors and infections risk: focus on herpes zoster.
Ther Adv Musculoskelet Dis. 2020 Jun 29;12:1759720X20936059. doi: 10.1177/1759720X20936059. eCollection 2020.
6
Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.
J Crohns Colitis. 2020 Sep 7;14(8):1162-1171. doi: 10.1093/ecco-jcc/jjaa036.
7
Is cytomegalovirus infection related to inflammatory bowel disease, especially steroid-resistant inflammatory bowel disease? A meta-analysis.
Infect Drug Resist. 2017 Dec 14;10:511-519. doi: 10.2147/IDR.S149784. eCollection 2017.
8
Alteration of glucocorticoid receptors and exacerbation of inflammation during lytic cytomegalovirus infection in THP-1 cells.
FEBS Open Bio. 2017 Oct 30;7(12):1924-1931. doi: 10.1002/2211-5463.12334. eCollection 2017 Dec.
9
The Association Between CMV Viremia or Endoscopic Features and Histopathological Characteristics of CMV Colitis in Patients with Underlying Ulcerative Colitis.
Inflamm Bowel Dis. 2017 May;23(5):814-821. doi: 10.1097/MIB.0000000000001095.
10
Diagnostic Accuracy of Blood-Based Tests and Histopathology for Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
Inflamm Bowel Dis. 2017 Apr;23(4):551-560. doi: 10.1097/MIB.0000000000001073.
Zotero 插件